IntroductionPolicy debates on trade and health care innovation often rest on the idea that the United States finances the world’s R&D, with high domestic drug spending underwriting discoveries that benefit patients globally. This view emphasizes US-funded research and the reinvestment of manufacturer revenues at home.1 However, it overlooks another crucial reality: the global capital markets […]
